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Introduction: KIF11, a mitotic kinesin, is a component responsible for 
assembly and maintenance of mitotic spindle during mitosis. Tumor cells 
can upregulate KIF11. Inhibition of KIF11 results monopolar spindle for-
mation, resulting in monoastral mitosis in cells. This activates the spindle as-
sembly checkpoint, cells are arrested and prevented from entering cell cycle, 
resulting in cell death via apoptosis or necrosis, cell division with aneuploidy 
or mitotic slippage without division into tetraploid G1 phase. Methods: We 
hypothesized that the effect of KIF11 inhibition on medulloblastoma (MB) 
is dependent of its p53 mutational status. Results: Our findings on Hoechst 
staining demonstrated a small molecule inhibitor of KIF11 which induced 
apoptosis in p53-wildtype MB cells at 48h (p<0.0001), was able to trigger 
mitotic catastrophe (p = 0.0010) in p53-mutant MB cells at 24h and subse-
quent necrosis (p=0.0039) at 48h. KIF11 inhibitor exerted anti-proliferative 
effects on five MB cell lines at nanomolar concentration range, independent 
of its p53 mutational status. Cells treated with KIF11 inhibitor were arrested 
in G2/M phase. Apoptosis was observed on Annexin V flow cytometry 24h 
after treatment, followed by necrosis after 48h in p53-wildtype cells. In con-
trast, treated p53-mutant cells underwent necrosis at 24h. Differences in 
cell death mechanisms upon KIF11 inhibition was confirmed on immuno-
blotting by upregulated p53 expression and presence of cleaved-PARP and 
DNA-damage marker in p53-wildtype cells, indicative of apoptosis. While 
inhibition of KIF11 and increased p53 expression were observed only after 
48h, cleaved-PARP expression was detected as early as 24h in p53-wildtype, 
suggesting KIF11-independent, cleaved-PARP-mediated cell death at 24h. 
In contrast, treated p53-mutant cells showed decreased p53 expression 
and absence of cleaved-PARP and DNA-damage marker after 24h. Conclu-
sions: Our results suggest that when mitotic arrest is induced, p53-mutant 
MB cells undergo mitotic catastrophe and necrosis while p53-wildtype MB 
cells predominantly undergo apoptosis.
EMBR-24. YB1 IS CRITICAL FOR MEDULLOBLASTOMA TUMOR 
MAINTENANCE AND DNA REPAIR FOLLOWING THERAPEUTIC 
INTERVENTION
Leon McSwain, Anna Kenney, Victor Chen, and Tiffany Huang; Emory 
University, Atlanta, GA, USA
Medulloblastoma (MB) is the most common pediatric central nervous 
system malignancy. Although the current standard of care leads to ~70% 
patient survival, the therapies are highly toxic, leading to life-long side ef-
fects, and recurrence due to therapeutic resistance is fatal. We sought to 
investigate mediators of radiation response in mouse models for the Sonic 
hedgehog (SHH) subgroup MB as well as human cell lines. We previously 
identified Y-box binding protein 1 (YB1) as a downstream effector of YAP-
mediated MB radiation resistance. YB1 is a crucial, yet understudied, protein 
highly expressed across all 4 subgroups of MB. Through its DNA- and 
RNA-binding cold shock domain, YB1 mediates both transcriptional and 
translational changes important for tumor maintenance and therapeutic re-
sponse. We show that following ionizing radiation, YB1 mediates DNA re-
pair through PARP and that PARP inhibition abrogates YB1-mediated DNA 
repair in cells overexpressing YB1. Additionally, through its inhibitory ef-
fects on p53, YB1 is capable of mediating anti-apoptotic effects in response 
to genotoxic insult. By targeting YB1 with short hairpin RNA, we show 
that cells are more amenable to ionizing radiation induced double strand 
breaks. Additionally, we utilize RNA binding protein immunoprecipitation 
sequencing to investigate post transcriptional regulation of RNAs bound by 
YB1. We show that YB1 binds numerous transcripts critical for the iden-
tity of early cerebellar progenitor cells, the putative cell of origin for SHH 
subgroup tumors, in addition to transcripts important for cell cycling and 
migration.
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Introduction: Medulloblastoma (MB) is the most common malig-
nant brain tumour in children. The most frequent molecular subgroup, 
Group 4 (MBGrp4) accounts for ~35/40% of cases, however it has the least 
understood underlying biology. Clinical outcomes are heterogeneous in 
MBGrp4 and are not accounted for by established clinico-pathological 
risk factors. There is now a requirement for a comprehensive study of 
MBGrp4, considering established clinico-pathological features and novel 
molecular biomarkers to enhance risk-stratification and identify novel 
therapeutic targets.  Methods: A clinically-annotated, retrospective 
MBGrp4 discovery cohort (n = 420) was generated from UK CCLG insti-
tutions, collaborating European centres and SIOP-UKCCSG-PNET3 and 
HIT-SIOP-PNET4 clinical trials. Contemporary, multi-omics profiling 
was performed. Focal and arm level copy number aberrations (CNAs) 
were determined from molecular inversion probe (MIP) or DNA methy-
lation array which additionally provided next generation non-WNT/
non-SHH (Grp3/Grp4) subtype classifications. Targeted next-generation 
DNA sequencing was performed to overlay the mutational landscape. 
Survival modelling was carried out with patients >3 years old who re-
ceived craniospinal irradiation. Results: MBGrp4 subtypes were assigned 
to 88% of tumours with available data. Subtype VIII was strongly asso-
ciated with i17q (p<0.0001). The favourable-risk cytogenetic signature 
(2 or 3 of; chromosome 7 gain, chromosome 8 loss and/or chromosome 
11 loss) associated with both subtypes VI and VII (p<0.0001). MYCN 
amplifications were strongly associated with subtype V (p<0.0001) in 
addition to 16q loss (p<0.0001). The high-risk CNA group was enriched 
for mutations in genes involved in chromatin remodelling (p<0.0001). 
Risk factors were identified from multivariate survival modelling. Sub-
type and CNA groups contributed to improved risk-stratification models 
that outperformed current clinical schemes. Conclusion: Comprehensive 
genetic and epigenetic profiling in this large retrospective cohort has im-
proved our understanding of the molecular and clinical heterogeneity 
within MBGrp4. Incorporation of molecular biomarkers improved risk-
stratification for MBGrp4.
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Medulloblastoma (MB) is a heterogeneous disease in which neoplastic 
cells and associated immune cells contribute to disease progression. To better 
understand cellular heterogeneity in MB we used single-cell RNA sequencing, 
immunohistochemistry and deconvolution of transcriptomic data to profile 
neoplastic and immune populations in childhood MB samples and MB gen-
etically engineered mouse models (GEMM). Neoplastic cells clustered pri-
marily according to individual sample of origin which is in part due to the 
effect of chromosomal copy number gains and losses. Harmony alignment 
of single cell transcriptomic data revealed novel MB subgroup/subtype-
associated subpopulations that recapitulate neurodevelopmental processes 
and are associated with clinical outcomes. This includes photoreceptor-like 
cells and glutamatergic lineage unipolar brush cells in both GP3 and GP4 
subgroups of MB, and a SHH subgroup nodule-associated neuronally-
differentiated cell subpopulation. We definitively chart the spectrum of MB 
immune cell infiltrates, which reveals unexpected degree of myeloid cell 
diversity. Myeloid subpopulations include subgroup/subtype-associated 
developmentally-related neuron-pruning as well as antigen presenting mye-
loid cells. Human MB cellular diversity is recapitulated in subgroup-specific 
MB GEMM, supporting the fidelity of these models. These findings provide 
a clearer understanding of both the neoplastic and immune cell heterogen-
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